Hawaii Biotech, Inc., a Hawaii-based biopharmaceutical company, announced today it has been awarded $15.5 million through three separate grants from the National Institutes of Health (NIH). The grants will fund pre-clinical development of the Company’s West Nile Virus and dengue vaccines and a significant portion of the Phase I human clinical trial for the dengue vaccine. These grants bring total federal funding for Hawaii Biotech’s Emerging Disease/Bioterrorism program to over $31 million, including $12 million in Department of Defense and NIH anthrax funding as well as smaller federally funded projects in ebola, malaria, and tick-borne encephalitis. The Company also has a self-funded flu program.
